

BG SALES-TRADING MORNING DU 10/02/2016

LA SEANCE DE LA VEILLE									
INDICES U.S & JAPON				SECTEURS S&P : BEST PERFS			SECTEURS STOXX : BEST PERFS		
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD
DJ	16014,4	-0,1%	0,4%	Transportation	1,2	-7,8	Media	0,4	-13,3
NASDAQ	4268,8	-0,3%	0,2%	Materials	1,2	-7,8	Technology	0,1	-14,1
S&P 500	1852,2	-0,1%	0,4%	Food Bev & Tobacco	0,9	-1,6	Travel & Leisure	0,1	-15,4
NIKKEI	15713,4	-2,3%	-	Health Equip.	0,8	-10,9	Retail	-0,4	-11
SECTEURS S&P : WORST PERFS.					SECTEURS STOXX : WORST PERFS				
				S&P	Var %	YTD	STOXX	Var %	YTD
				Oil & Gaz	-2,5	-8,6	Basic Resources	-5,4	-12,5
				MEDIAS	-1,9	-6	Banks	-4	-27,3
				Real Estate	-1,8	-12,1	Oil & Gas	-3,2	-10,4
				Auto	-1,1	-19,3	Insurance	-2,6	-21,4

Valeurs les plus traitées hier vs. Moy. 3M									
CAC 40			EURO STOXX 50			STOXX 600			
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%	
CAP GEMINI	73,4	-0,3	BNP PARIBAS	37,9	-3,6	GAMESA CORP	16,5	5,6	
BOUYGUES SA	32,2	-0,4	ING GROEP NV-CVA	9,4	-4,8	PANDORA A/S	764	-7,3	
PERNOD RICARD SA	98,3	-2	INTESA SANPAOLO	2,1	-6,2	SWEDBANK AB - A	157,8	-5,7	
BNP PARIBAS	37,9	-3,6	UNIBAIL-RODAMCO	217,6	-2	MERLIN PROPERTIES	9,2	-4,4	
UNIBAIL-RODAMCO	217,6	-2	ABUSCH INBEV SA/NV	103,2	0,2	HOWDEN JOINERY	457,4	0,2	

DEFINITION : * compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVISES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	100,1	0%	0,7%	€/§	1,1283	-0,1%	3,9%	BRENT	30,6	0,7%	-14,5%
U.S 10 ANS	104,8	0,1%	1,7%	€/¥	129,5	0,4%	0,9%	ONCE OR (§)	1189,9	0,1%	12,1%
VIX Index	26,5		2,1%					VSTOXX Index	34		1,7%

Economic Calendar

CNY - New yuan Loans Jan. (1900n E)
 JP - housing Loans 4Q
 GB - industrial Prod. Dec. (-1.4% E y/y)
 US - J Yellen to appear before House Financial Serv. Committee

Dividends Calendar ex-date next day

SAGE (SGE.L) 8.65p (1.49%)
 BP (BP.L) 0.1§ (2%)
 IGE+XAO (ICXA.PA) 1€ (1.52%)

Ex Div today

TUI (TUIT.L) 0.56€ (4%)
 EUROMEDIS (EUMD.PA) 0.12€ (1.85%)

Markets Recap (source Street account)

Asian markets are trading lower Wednesday. Volatility remains elevated with banks coming under further pressure in Japan and Australia. Reports that Deutsche Bank (DBK.GR) is considering a buyback of its senior debt appears to have offered little respite for sentiment. Bond market weakness is also garnering more discussion with troubled European contingent convertible debt in focus. Bond markets have nonetheless steadied from Tuesday's turbulence with the 10Y JGB inching back above zero. The Nikkei's sell-off is coinciding with some yen strength while Japanese press has highlighted depressed stock valuations and a projected impact on GDP from the recent volatility. Selling momentum intensified earlier on the ASX with major banks again leading declines. Index heavyweight Commonwealth Bank (CBA.AU) is outperforming after its H1 earnings beat. There is also an element of trepidation with Fed Chair Yellen due to testify before Congress tonight. Yellen is seen acknowledging recent financial tightness but reiterating data dependency.

US equities closed slightly lower today, though sectors were mixed. Treasuries were mixed, with some curve flattening. The dollar was weaker, particularly on the euro cross. Gold was little changed after yesterday's rally. Copper was lower. Oil posted a sharp decline, with WTI settling (5.9%) and Brent

settling (7.8%).

There were few broad macro factors at play today, with much of the commentary instead revolving around the ongoing weakness in banks and the recent widening in CDS spreads. Oil was weaker after an IEA report highlighted oversupply trends. The Labor Department's JOLTS report provided additional evidence for a strong domestic labor market.

VIAB beat on advertising, but missed on affiliate fees. FOXA lowered F16 EBITDA guidance, but largely due to FX. GPS posted a worse-than-expected comp decline, but its Q4 EPS guide was better. WEN beat on comps, and KO saw better volume growth. Commodity-equity weakness was once again in evidence, with RIO, BHP, and MT lower on downgrades.

Materials led despite weakness in industrial metals. Managed-care names were up. Airlines were better. Banks were mixed. Tech lagged, but software was a relative outperformer. Energy was the worst performer

Stocks Factor to watch today :

ORPEA : 4Q rose 22% to 650.4m€ and forecast that 2016 revenue would rise 13.7% to 2.72bn.

NUMERICABLE : Michel Combes said that SFR had stabilised its mobile subscriber base in the 3Q and that the trend had been confirmed in the 4th.

HEINEKEN : Organic revenue +3.5%, revenue per HL +1.3%, hikes dividend 1.3€ will be proposed up +18%, upbeat for 2016, expects further volatility in emerging market and deflationary pressures in 2016

Rating & TP Changes



ZURICH INSURANCE : NEUTRAL vs. UNDERWEIGHT @JPM

VESTAS : TP raised to 550DKK vs. 510 OVERWEIGHT @ Barclays

CAMPARI : TP raised to 6.75€ vs. 6.5, UNDERWEIGHT @ Barclays

ACTELION: BUY vs. HOLD, TP raised to 155CHF vs. 150 @HSBC

ADIDAS : TP raised to 108€ vs. 101, BUY @HSBC

H&M : BUY vs. NEUTRAL @ UBS

TOTAL : added to CITI FOCUS LIST EUROPE @ CITI



SANOFI : TP cut to 88€ vs. 90, NEUTRAL @BRYAN GARNIER

SANOFI : TP cut to 79€ vs. 91, Market perform @Bernstein

SANOFI : TP Cut to 107€ vs. 115, BUY @ SOCGEN

SANOFI : TP cut to 77€ vs. 82, UNDERWEIGHT @JPM

ADIDAS : TP cut to 87€ vs. 90, NEUTRAL @CREDIT SUISSE

ACTELION : TP cut to 142CHF vs. 152, NEUTRAL @JPM

ARCELORMITTAL : TP cut to 3.1€ vs. 5n NEUTRAL @ CITI

Technical Analysis

Upward Signals

Downward Signals

Bryan Garnier ... Today's comment(s)

Orpea

RATING : BUY

Fair Value EUR76 (+14%)

The group unveiled its FY 2015 revenue, up 22.8% on reported basis at EUR2,393m with lfl growth of 5.4% (5.1% in Q4), i.e. slightly ahead of consensus (consensus at EUR2,386m and our estimate of EUR2,390m) and group guidance of EUR2,380m which was twice revised in 2015.

2016 well on track to be another year of solid revenue growth: With still sustained lfl revenue growth and taking into account the full year consolidation of acquisitions in **Germany** i.e. (Residenz Gruppe Bremen, Vitalis, Celenus Kliniken) and in **Poland** (MEDI-System), **management expects to reach total revenue of EUR2,720m (+13.7%).**

Positive.

Coface	RATING : NEUTRAL	Fair Value EUR10.5 (+55%)
---------------	-------------------------	----------------------------------

Q4/FY 2015 are pretty much in line with expectations, with a EUR126m FY net income and a 83.1% FY combined ratio (vs. 79.7% in 2014). The dividend is stable at EUR0.48 (7.1% yield). As expected, most 2016 targets have been dropped. The solvency II ratio at end-2015 is 147% using the standard. No detail on the restructuring plan to contain (at least partially) the loss of the public guarantee business. For sure, incoming CEO Xavier Durand has a lot of work to do! Our theoretical model shows upside potential, yet we stick to a Neutral recommendation as the business momentum is not supportive and we lack visibility on the restructuring plan.

Sanofi	RATING : NEUTRAL	Fair Value EUR88 vs. EUR90 (+28%)
---------------	-------------------------	--

The guidance provided for 2016 looks very much balanced in its underlying assumptions. Although time is required to make a full assessment on the delivery of top-line growth with new products, the cost base is under control in the meantime and we see no meaningful risk of deviation from a central scenario of flat earnings from 2015 to 2017. With a P/E ratio of 12-12.5x over the period, the stock starts looking attractive again in absolute terms. Our NEUTRAL rating reflects a poor momentum (H1 will be tougher than H2) and preference for the UK peers.
